XML 76 R42.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Acquisitions (Details Textual) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2018 | Mar. 31, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017
Business Acquisition [Line Items] |  |  |  |  |
Acquired in-process research and development | $ 75.0 |  | $ 120.0 | $ 85.0 | $ 120.0
Karyopharm |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Acquired in-process research and development |  | $ 10.0 |  |  |
Estimated additional payments upon achievement of milestones |  |  |  | 207.0 |
Pfizer |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Acquired in-process research and development | 75.0 |  |  |  |
Estimated additional payments upon achievement of milestones |  |  |  | 515.0 |
TMS |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Acquired in-process research and development |  |  |  | 18.0 |
Estimated additional payments upon achievement of milestones |  |  |  | 335.0 |
Research and development expense asset acquired | $ 4.0 |  |  |  |
Development Milestones | Pfizer |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Estimated additional payments upon achievement of milestones |  |  |  | $ 10.0 |

X
- Definition Estimated additional payments upon achievement of development and commercial milestones. + References No definition available. + Details
Name: | biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=biib_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=biib_TMSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |